Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo

Journal of Molecular Neuroscience

Volumn 33, Issue 3, 2007, Pages 278-283

  Giladi, Eliezer ^a   Hill, Joanna M ^b   Dresner, Efrat ^a   Stack, Conor M ^c   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; BRAIN PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; EMBRYO DEVELOPMENT; HYPOTHALAMUS; IN VIVO STUDY; MOUSE; NEURAL TUBE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BRAIN; FEMALE; HOMEODOMAIN PROTEINS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NEURULATION; PREGNANCY; PROTEIN ISOFORMS; VASOACTIVE INTESTINAL PEPTIDE;

MUS;

EID: 36949019759     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-007-9003-0     Document Type: Article

References (36)

1. Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., et al. (1999). Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. Journal of Neurochemistry, 72, 1283-1293.
2. Blondel, O., Collin, C., McCarran, W. J., Zhu, S., Zamostiano, R., Gozes, I., et al. (2000). A glia-derived signal regulating neuronal differentiation. Journal of neuroscience, 20, 8012-8020.
3. Brenneman, D. E., & Gozes, I. (1996). A femtomolar-acting neuroprotective peptide. Journal of Clinical Investigation, 97, 2299-2307.
4. Brenneman, D. E., Neale, E. A., Foster, G. A., d'Autremont, S. W., & Westbrook, G. L. (1987). Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. Journal of Cell Biology, 104, 1603-1610.
5. Colwell, C. S., Michel, S., Itri, J., Rodriguez, W., Tam, J., Lelievre, V., et al. (2003). Disrupted circadian rhythms in VIP- and PHI-deficient mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 285, R939-R949.
6. Eilam, R., Davidson, A., Gozes, I., & Segal, M. (1999). Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus. Hippocampus, 9, 534-541.
7. Furman, S., Hill, J. M., Vulih, I., Zaltzman, R., Hauser, J. M., Brenneman, D. E., et al. (2005). Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neuroscience Letters, 373, 73-78.
8. Girard, B. A., Lelievre, V., Braas, K. M., Razinia, T., Vizzard, M. A., Ioffe, Y., et al. (2006). Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice. Journal of Neurochemistry, 99, 499-513.
9. Glowa, J. R., Panlilio, L. V., Brenneman, D. E., Gozes, I., Fridkin, M., & Hill, J. M. (1992). Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Research, 570, 49-53.
10. Gozes, I. (1988). Biosynthesis and regulation of expression. The vasoactive intestinal peptide gene. Annals of the New York Academy of Sciences, 527, 77-87.
11. Gozes, I., Avidor, R., Yahav, Y., Katznelson, D., Croce, C. M., & Huebner, K. (1987). The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21-6qter. Human Genetics, 75, 41-44.
12. Gozes, I., Bardea, A., Bechar, M., Pearl, O., Reshef, A., Zamostiano, R., et al. (1997). Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Annals of the New York Academy of Sciences, 814, 161-166.
13. Gozes, I., Bardea, A., Reshef, A., Zamostiano, R., Zhukovsky, S., Rubinraut, S., et al. (1996). Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proceedings of the National Academy of Sciences of the United States of America, 93, 427-432.
14. Gozes, I., Glowa, J., Brenneman, D. E., McCune, S. K., Lee, E., & Westphal, H. (1993). Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. Journal of Molecular Neuroscience, 4, 185-193.
15. Gozes, I., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, I. E., Davidson, A., et al. (1995). Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. Journal of Pharmacology and Experimental Therapeutics, 273, 161-167.
16. Gozes, I., McCune, S. K., Jacobson, L., Warren, D., Moody, T. W., Fridkin, M., et al. (1991). An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. Journal of Pharmacology and Experimental Therapeutics, 257, 959-966.
17. Gozes, I., Meltzer, E., Rubinrout, S., Brenneman, D. E., & Fridkin, M. (1989). Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Endocrinology, 125, 2945-2949.
18. Gozes, I., Schachter, P., Shani, Y., & Giladi, E. (1988). Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology, 47, 27-31.
19. Granoth, R., Fridkin, M., Rubinraut, S., & Gozes, I. (2000). VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. FEBS Letters, 475, 71-77.
20. Gressens, P., Besse, L., Robberecht, P., Gozes, I., Fridkin, M., & Evrard, P. (1999) Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. Journal of Pharmacology and Experimental Therapeutics, 288, 1207-1213.
21. Gressens, P., Hill, J. M., Gozes, I., Fridkin, M., & Brenneman, D. E. (1993). Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature, 362, 155-158.
22. Gressens, P., Hill, J. M., Paindaveine, B., Gozes, I., Fridkin, M., & Brenneman, D. E. (1994). Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. Journal of Clinical Investigation, 94, 2020-2027.
23. Hill, J. M., Cuasay, K., & Abebe, D. T. (2007a). Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring. Experimental Neurology, 206, 101-113.
24. Hill, J. M., Glazner, G. W., Lee, S. J., Gozes, I., Gressens, P., & Brenneman, D. E. (1999). Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor. Annals of the New York Academy of Sciences, 897, 92-100.
25. Hill, J. M., Hauser, J. M., Sheppard, L. M., Abebe, D., Spivak-Pohis, I., Kushnir, M., et al. (2007b). Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. Journal of Molecular Neuroscience, 31, 183-200.
26. Holtzman, R. L., Malach, R., & Gozes, I. (1989). Disruption of the optic pathway during development affects vasoactive intestinal peptide mRNA expression. New Biologist, 1, 215-221.
27. Mandel, S., Rechavi, G., & Gozes, I. (2007). Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Developments in Biologicals, 303, 814-824.
28. Pinhasov, A., Mandel, S., Torchinsky, A., Giladi, E., Pittel, Z., Goldsweig, A. M., et al. (2003). Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Research. Developmental Brain Research, 144, 83-90.
29. Sigalov, E., Fridkin, M., Brenneman, D. E., & Gozes, I. (2000). VIP-related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. Journal of Molecular Neuroscience, 15, 147-154.
30. Spong, C. Y., Lee, S. J., McCune, S. K., Gibney, G., Abebe, D. T., Alvero, R., et al. (1999). Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. Endocrinology, 140, 917-924.
31. Szema, A. M., Hamidi, S. A., Lyubsky, S., Dickman, K. G., Mathew, S., Abdel-Razek, T., et al. (2006). Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. American Journal of Physiology. Lung Cellular and Molecular Physiology, 291, L880-L886.
32. Wu, J. Y., Henins, K. A., Gressens, P., Gozes, I., Fridkin, M., Brenneman, D. E., et al. (1997). Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides, 18, 1131-1137.
33. Zaltzman, R., Alexandrovich, A., Beni, S. M., Trembovler, V., Shohami, E., & Gozes, I. (2004). Brain injury-dependent expression of activity-dependent neuroprotective protein. Journal of Molecular Neuroscience, 24, 181-187.
34. Zamostiano, R., Pinhasov, A., Bassan, M., Perl, O., Steingart, R. A., Atlas, R., et al. (1999). A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. Neuroscience Letters, 264, 9-12.
35. Zamostiano, R., Pinhasov, A., Gelber, E., Steingart, R. A., Seroussi, E., Giladi, E., et al. (2001). Cloning and characterization of the human activity-dependent neuroprotective protein. Journal of Biological Chemistry, 276, 708-714.
36. Zusev, M., & Gozes, I. (2004). Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regulatory Peptide, 123, 33-41.